Genenta Science is leveraging its Temferon™1 technology platform to treat cancers using a novel immuno-gene therapy approach
is an Investigational Advanced Therapy Medicinal Product (ATMP) consisting of autologous CD34+-TEM enriched Hematopoietic Stem and Progenitor Cells (HSPC) transduced with a Lentiviral Vector (LV) encoding the human interferon-α2 (IFN-α2) gene. The expression of the gene within the tumor microenvironment is regulated by TEM-specific promoter and microRNA-126 (miR-126).
For more details about our studies:
ClinicalTrials.gov Identifier: NCT03866109
Italian translation: NCT03866109
ClinicalTrialRegister EU identifier: https://www.clinicaltrialsregister.eu/ctr-search/trial/2018-001404-11/IT
: The enrollment of the first patient is anticipated in 1Q21